US-based 3D bioprinting firm Organovo has set itself a challenge that could transform the future of medicine, and although the technology is still in its infancy and the challenges complex, the company’s founder and CEO Keith Murphy says his firm is in it for the long haul.
“Biotechnology is a very compelling space as you have the ability to impact people’s lives,” Murphy tells IBTimes UK. “I want to see patients benefiting. We want to help drugs get to patients faster, to get liver tissues [to prolong liver function] and to help people with chronic liver problems.”
Hey, check out all the engineering jobs. Post your resume today!
